Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. - Wikidata - awgldk - TriplyDB

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

http://www.wikidata.org/entity/Q53123391

about

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use New agents for the treatment of drug-resistant Mycobacterium tuberculosis Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Extensively drug-resistant tuberculosis: epidemiology and management WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis Vaccines for TB: Lessons from the Past Translating into Future Potentials New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid New insights into TB physiology suggest untapped therapeutic opportunities New anti-tuberculosis drugs and regimens: 2015 update Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Binding and processing of β-lactam antibiotics by the transpeptidase LdtMt2 from Mycobacterium tuberculosis.Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.Non-classical transpeptidases yield insight into new antibacterials Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.Tuberculosis treatment and drug regimens.Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.The multidrug-resistant tuberculosis threat: old problems and new solutions Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases.Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.Drug-Resistant Tuberculosis: Challenges and Progress.Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.WHO strategies for the programmatic management of drug-resistant tuberculosis.An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.News on therapeutic management of MDR-tuberculosis: a literature review.Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method.

P2860

Q26741138-D68B2B1F-53AF-4864-A7D4-149C54D95172 Q26751463-F39EEC9D-A2F3-407D-8AEE-93B49A883F5F Q26764847-B5FA4216-E8C5-49F5-A9AA-2E412FB7AE62 Q26771997-2183AFFB-1CCF-4D50-9B0A-685C19903EF3 Q26830094-36B99490-7B2B-4B1E-9F90-D4DE0BBFDFE0 Q26852253-4A792C0E-37F8-4D6F-8AB1-263B632B69F9 Q26996673-81A62AD6-21A0-433C-85BC-8EC7EF516A1B Q27003210-656F94D0-7F31-4CFE-934B-D300B5399553 Q28388477-988B436D-FBC1-4A72-97BE-04D582BCE4A5 Q28596775-BAEC3C9B-C5D4-4089-A5D4-9516207D29ED Q30236048-CB094A7E-BF22-42C1-BA6E-24541D0B0083 Q30397294-6D52CE86-0DC8-4A45-BA96-9D42458673D4 Q30573127-4E3F2BDD-10A4-447B-BF58-C1895AA7A2BC Q30620897-B0B44DBF-DB4F-4148-86D1-437AB41F83AB Q33814192-A459FEAF-7EAB-48EF-A337-0BC7318E382B Q33926262-EE09897C-DBA0-41FC-B3E2-F0486A5E22A5 Q34150992-BB2BF419-D56F-4372-AC50-3A31110D5768 Q34229876-FC0277DB-E4D8-4FE3-A275-412596F16107 Q35032535-0C6B3586-65D7-46B1-8B95-8220AF1EC606 Q35125060-B69B5FA8-A3C7-47E9-8FE2-16FC9A8166B3 Q35663866-ECAEB863-61E5-4B21-B6C9-4C0503447FAE Q35860128-93829EE4-D52C-429C-BEB0-9102577D1B61 Q36094215-E0318A54-EB77-4DA6-A769-7B36E77453DA Q36138237-210FEE40-775C-4FAB-8C79-E61E47EB35C9 Q36355735-C384C72D-1ABD-4596-9D88-8247DBF397CA Q36438910-19EAF727-50E4-47E5-8792-CC2AF8D0CC87 Q36490639-193ADBA4-DFB4-4F57-BD86-F570B78626B7 Q36888124-60560F5B-0E4D-4CC3-8A10-70AF12CEED0A Q36924283-AA3C30E7-3BC3-479A-9841-FD7131B714C5 Q38232824-4A957E87-FAAE-485C-8922-048BD03A4954 Q38724073-0FAD3186-A30B-43E1-A5B2-DF01EA82DE7C Q38763608-77F2F940-7CC0-4AF3-AD57-A7DE6DE7AC7B Q38777085-DF6F1E86-E861-4AEE-A442-9DD081ED4748 Q38856343-D4BA9448-4F3A-4876-A87B-DC434424DD2F Q38885365-049A20E9-1BA5-4C72-B25A-C1DD3ACEAF40 Q39038482-064E2D2C-A3B9-4E4D-8F1E-1B5A19A4453C Q39398924-C38C5C0B-F764-45FE-8FDC-4C856BA64D31 Q40080040-54B4FC90-7CAC-49C9-B70F-8F3E6A8A1A3F Q40675039-FFB42453-FEBC-4A66-B743-FD1FD15E376A Q41075817-AAB315D5-EB2C-4593-A660-878A2E153398

P2860

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

http://www.wikidata.org/entity/Q53123391

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@en

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@nl

type

label

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@en

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@nl

prefLabel

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@en

Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.

@nl

P1433

Q53123391-9F2E4E5B-40B9-4B14-931D-038061419719

P1476

Q53123391-8B1DB90E-11F7-4A85-B797-141D2DFD6D3C

P2093

Q53123391-1171C383-6FDB-4FF7-8C68-F9D5430E44CD

Q53123391-67C66791-DC5C-4FCC-869E-CFFFEE4D0056

Q53123391-693ABB51-0F4C-4D46-9B03-C606F9120E9F

Q53123391-6FCF4D35-60C3-4D27-BDAC-2352817F4199

Q53123391-D2C2D34D-20AD-47D9-A939-1724091AF1B9

Q53123391-F145CEB3-A2ED-4568-B026-79729C406C72

P304

Q53123391-623436C8-91EE-412C-AD9C-C9BCB77C137B

P31

Q53123391-2C314977-D4F8-4B0B-94F1-DC2FA6A57C4D

P356

Q53123391-95B36801-24DE-4965-BE9C-7467C3213D23

P433

Q53123391-6F36221A-0EF6-4195-8D69-9714F8991FBF

P478

Q53123391-A70463A9-3305-48BE-8F17-0EBADDEEE6C7

P50

Q53123391-21429989-9ED1-4D3F-8587-2D024CF076EB

Q53123391-40231BE6-0821-4ADF-B06F-8E45041D1ED3

Q53123391-40E783AB-0C21-44EF-A2D9-30151996AC13

Q53123391-7A4ED72E-81A7-4635-B909-3C65463A8D6C

Q53123391-8B55DF46-7F4C-44B6-9966-C19232B6A02C

Q53123391-CE2246A3-DB60-4AC6-B662-74663B21D0DA

Q53123391-D5A72455-00FC-4CF0-A178-477C9A6269C6

P577

Q53123391-BE8D10D7-0A64-4EAA-B977-11864304EF00

P5875

Q53123391-42DF8A06-39D9-4A86-A9B9-75724B4FB8C2

P698

Q53123391-2DBB5CB3-577D-4877-9AFD-8F2F37E3B6BD

P356

09031936.00124312

P1433

European Respiratory Journal

P1476

Efficacy and safety of meropen ...... n the treatment of MDR-/XDR-TB

@en

P2093

Jan Wilem Alffenaar

http://www.w3.org/2001/XMLSchema#string

Lia D'Ambrosio

http://www.w3.org/2001/XMLSchema#string

Mathieu S Bolhuis

http://www.w3.org/2001/XMLSchema#string

Piero Viggiani

http://www.w3.org/2001/XMLSchema#string

Richard van Altena

http://www.w3.org/2001/XMLSchema#string

Saverio De Lorenzo

http://www.w3.org/2001/XMLSchema#string

P304

1386-1392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.00124312

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Battista Migliori

Giovanni Sotgiu

Antonio Spanevello

P577

2012-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230895626

http://www.w3.org/2001/XMLSchema#string

P698

22997218

http://www.w3.org/2001/XMLSchema#string